News
Opko Health Inc. (NASDAQ:OPK) is one of the 13 Stocks Under $5 With High Upside Potential. On May 1, analyst Yi Chen of H.C.
OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company. The company is engaged in discovering, developing, commercializing and expertise ...
Opko Health Inc. (NASDAQ:OPK) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. In a report released on May 2, Edward Tenthoff from Piper Sandler reiterated a Buy rating on ...
MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic ...
Opko Health (NYSE: OPK) is a mid-cap pharmaceutical stock with several corporate growth strategies: clinical drugs, medical devices, and strategic acquisitions. Of particular interest to many ...
OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and ...
Healthcare company OPKO Health Inc has agreed to pay $10 million to resolve allegations that a unit that provides laboratory services rented office space from doctors at above-market rates so the ...
Robert Grossman, Ira Rosner and Joshua Samek led a large team of Greenberg Traurig attorneys who represented Opko Health in its $1.47 billion acquisition of Bio-Reference Laboratories.
Opko Health Inc. (NASDAQ:OPK) is one of the 13 Stocks Under $5 With High Upside Potential. On May 1, analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Opko Health Inc.
OPKO Health is witnessing a positive estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for its loss has narrowed from 26 cents to 23 cents per share.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results